Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED)

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS` EQUITY (UNAUDITED) - 9 months ended Jul. 31, 2018 - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total Shareholders Equity [Member]
Noncontrolling Interest [Member]
Total
Balance, October 31, 2017 at Oct. 31, 2017 $ 166,028 $ 163,931,079 $ (156,174,184) $ 7,922,923   $ 7,922,923
Balance, October 31, 2017 (in Shares) at Oct. 31, 2017 16,602,759          
Stock option compensation to employees and directors   3,598,986   3,598,986   3,598,986
Stock option compensation to consultants   197,040   197,040   197,040
Common stock issued upon exercise of stock options $ 398 (398)        
Common stock issued upon exercise of stock options (in Shares) 39,816          
Common stock award issued to employee pursuant to stock incentive plan $ 15,000 1,358,940   1,373,940   1,373,940
Common stock award issued to employee pursuant to stock incentive plan (in Shares) 1,500,000          
Warrants issued to consultant   57,050   57,050   57,050
Common stock issued to consultants $ 53 14,949   15,002   15,002
Common stock issued to consultants (in Shares) 5,347          
Common stock issued in at-the-market offering $ 5,482 1,780,547   1,786,029   1,786,029
Common stock issued in at-the-market offering (in Shares) 548,224          
Issuance of noncontrolling interest in Certainty Therapeutics, Inc   68,974   68,974 $ (4,318) 64,656
Net loss     (8,693,532) (8,693,532) (158,032) (8,851,564)
Balance, July 31, 2018 at Jul. 31, 2018 $ 186,961 $ 171,007,167 $ (164,867,716) $ 6,326,412 $ (162,350) $ 6,164,062
Balance, July 31, 2018 (in Shares) at Jul. 31, 2018 18,696,146